Article

Olopatadine 0.2% provides extended efficacy during peak pollen periods

Fort Lauderdale, FL-A new formulation of an anti-allergy medication, olopatadine HCl ophthalmic solution 0.2% (Patanol II, Alcon Laboratories), provides two important advantages. It allows once-daily dosing, which increases patient compliance, and maintains the level of effectiveness of the original formulation, olopatadine 0.1%, during peak pollen seasons for an extended period up to 24 hours, according to Jack Greiner, DO, PhD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
Related Content
Precautionary recall announced for specific batch of Zaditen eye drops in the UK
July 8th 2025

Precautionary recall announced for specific batch of Zaditen eye drops in the UK

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Beacon Therapeutics completes enrollment in phase 2/3 VISTA trial
July 8th 2025

Beacon Therapeutics completes enrollment in phase 2/3 VISTA trial

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Boehringer Ingelheim launches phase 2 study of oral therapy for diabetic macular edema
July 8th 2025

Boehringer Ingelheim launches phase 2 study of oral therapy for diabetic macular edema

LENZ Therapeutics and Laboratoires Théa partner to commercialize LNZ100 for presbyopia in Canada
July 8th 2025

LENZ Therapeutics and Laboratoires Théa partner to commercialize LNZ100 for presbyopia in Canada

© 2025 MJH Life Sciences

All rights reserved.